LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

LLY

1,023.96

+0.31%↑

JNJ

196.01

+0.34%↑

ABBV

232.37

0%↓

UNH

321.37

-3.25%↓

AZN

89.14

+0.64%↑

Strona główna・Stock List・Design Therapeutics Inc

Design Therapeutics Inc

Closed

7.35 3.96

Buy Sell

Overview

Share price change

24h

Current

Min

7.29

Max

7.49

Key metrics
By Trading Economics
Income	2.1M -17M
Profit margin	-2,321.599
Employees	55
EBITDA	2.4M -19M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-18.59% downside

Market Stats
By TradingEconomics
Market Cap	50M 423M
Previous open	3.39
Previous close	7.35

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

3.26 / 3.63 Support & Resistance

Design Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 lis 2025, 17:45 UTC

Earnings

Major Market Movers

Figure Technology Shares Rise After Higher 3Q Earnings, Revenue

14 lis 2025, 17:31 UTC

Earnings

Major Market Movers

American Bitcoin Advances on 3Q Profit, Eric Trump's Crypto Confidence

16 lis 2025, 23:40 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

16 lis 2025, 23:36 UTC

Market Talk

Nikkei May Edge Lower Amid Lingering Worries Over Elevated Tech Valuations -- Market Talk

16 lis 2025, 23:26 UTC

Market Talk

RBA Policy Meetings May Contain a Trap for Traders -- Market Talk

16 lis 2025, 16:20 UTC

Earnings

Fed Minutes, Plus Walmart, Target, Home Depot, Nvidia, and More Stocks to Watch This Week -- Barrons.com

15 lis 2025, 09:20 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

15 lis 2025, 09:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

15 lis 2025, 00:08 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 3rd Update

14 lis 2025, 23:56 UTC

Acquisitions, Mergers, Takeovers

Berkshire Hathaway Bought Alphabet Shares Worth $4.3 Billion in the Third Quarter. Here's What It Sold. -- Barrons.com

14 lis 2025, 23:02 UTC

Market Talk

Chinese Battery Makers Benefit From U.S. Rising Demand -- Market Talk

14 lis 2025, 22:35 UTC

Earnings

Acquisitions, Mergers, Takeovers

The Score: Tyson, Robinhood, Walmart, Paramount Skydance and More Stocks That Defined the Week -- WSJ

14 lis 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- 2nd Update

14 lis 2025, 22:29 UTC

Earnings

Starbucks Scores on Holiday Sales. It's a Good Sign for the Turnaround. -- Barrons.com

14 lis 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Further Pares Apple Stake -- Update

14 lis 2025, 21:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

14 lis 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys Shares of Alphabet and Pares Apple Stake -- WSJ

14 lis 2025, 20:27 UTC

Market Talk

Oil Futures Rise After Ukraine Strikes Russian Port -- Market Talk

14 lis 2025, 20:23 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gain -- Market Talk

14 lis 2025, 20:17 UTC

Acquisitions, Mergers, Takeovers

Several State Attorneys General Oppose Railroad Merger -- WSJ

14 lis 2025, 19:29 UTC

Market Talk

Earnings

Applied Materials' F4Q Results Seen as 'Uninspiring' -- Market Talk

14 lis 2025, 18:44 UTC

Market Talk

Earnings

Disney's Growth Now Hinges More on ESPN -- Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Global Equities Roundup: Market Talk

14 lis 2025, 18:27 UTC

Market Talk

Morgan Stanley Sees 'Worthy Successor' in Walmart CEO Furner -- Market Talk

14 lis 2025, 18:20 UTC

Market Talk

U.S. Oil Rig Count Rises by 3 to 417 -- Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

14 lis 2025, 17:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

14 lis 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

14 lis 2025, 16:51 UTC

Market Talk

Starbucks Gets Holiday Sales Lift -- Market Talk

14 lis 2025, 16:48 UTC

Market Talk

Gold Slides Amid Selloff, Lower December Fed Rate-Cut Expectations -- Market Talk

Peer Comparison

Price change

Design Therapeutics Inc Forecast

Price Target

By TipRanks

-18.59% downside

12 Months Forecast

Average 6 USD -18.59%

High 6 USD

Low 6 USD

Based on 1 Wall Street analysts offering 12 month price targets forDesign Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Design Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.26 / 3.63Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.